Evolving

Late-breaking oral presentation to showcase preliminary safety, tolerability, clinical activity, and pharmacokinetics data of ALTA3263 in monotherapy and in combination with cetuximab

Former Poseida Therapeutics CFO joins Alterome Therapeutics as the company prepares to accelerate development of KRAS-targeting medicines

Veteran medical oncologist with a proven track record of advancing cancer therapies from early trials through regulatory approval to lead ongoing clinical development of ALTA2618 and ALTA3263

Alterome Therapeutics today announced the appointment of Jung Choi as Chief Executive Officer and Richard Heyman as Chair of the Board of Directors.

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.

Alterome Therapeutics, Inc., a clinical stage biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the dosing of the first patient in AKTive-001, a Phase 1/1b trial of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain.